Skip to content
Therapy But Better – Lifestyle
Author:
NovelMed Therapeutics Inc
NovelMed Advances NM5072 for Multiple Ocular Disorders
August 11, 2026
NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases
August 11, 2026
NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH
March 26, 2026